Viloxazine ER Maintains Safety, Efficacy for Long-Term Pediatric ADHD Treatment

 ADHD in the News 2023-11-02

Extended-release (ER) viloxazine demonstrates continued safety and efficacy with long-term use for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, according to results presented at the American Academy of Child and Adolescent Psychiatry (AACAP) 2023 Annual Meeting, held from October 23 to 28, 2023 in New York, New York.